Mereo BioPharma Details Anti-TIGIT Study And Attracts US Investors
Raises $70m In Private Placement
Mereo BioPharma’s completed private placement in the US will support clinical studies of its candidate immuno-oncology product etigilimab and a later-stage anti-sclerotin antibody product with potential in the treatment of brittle bone disease.
You may also be interested in...
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.
The 10-year partnership brings Arcus up-front funding with ample earnout opportunities, while Gilead gets extensive opt-in rights and an equity stake it can increase – and potentially a wholly owned dual checkpoint combination.